PIK3CA and ESR1 mutations detected in circulating tumor DNA (ctDNA) are predictive factors for late-line hormone-based therapies in ER+/HER2-metastatic breast cancer (MBC)

被引：0
|
作者：
Chen, Tom Wei-Wu [1 ]
Dai, Ming-Shen [2 ]
Chang, Dwang-Ying [1 ]
Lin, Ching-Hung [3 ]
Chen, I-Chun [3 ]
Wang, Ming-Yang [1 ]
Huang, Ling-Yi [4 ]
Hsu, An [4 ]
Zhuo, De-Wei [4 ]
Tan, Kien Thiam [4 ]
Lu, Yen-Jung [4 ]
Chang, Shu-Han [1 ]
Cheng, Ann-Lii [3 ]
Lu, Yen-Shen [1 ]
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] Triserv Gen Hosp, Taipei, Taiwan
[3] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan
[4] ACT Genom Co Ltd, Taipei, Taiwan
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P5-01-21
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P5-01-21
引用
收藏
页数：3
相关论文
共 46 条
  • [31] Prognostic values of cell free DNA, CA 15.3, and ESR1 circulating mutations variations in hormone receptor (HR)-positive metastatic breast cancer (MBC) patients under aromatase inhibitor (AI).
    Augusto, Laetitia
    Beaussire, Ludivine
    Lequesne, Justine
    Perdrix, Anne
    Sefrioui, David
    Fontanilles, Maxime
    Leheurteur, Marianne
    Di Fiore, Frederic
    Sarafan-Vasseur, Nasrin
    Clatot, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [32] Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant (vol 28, pg 1500, 2022)
    Tolaney, Sara M.
    Toi, Masakazu
    Neven, Patrick
    Sohn, Joohyuk
    Grischke, Eva-Maria
    Llombart-Cussac, Antonio
    Soliman, Hatem
    Wang, Hong
    Wijayawardana, Sameera
    Jansen, Valerie M.
    Litchfield, Lacey M.
    Sledge, George W., Jr.
    CLINICAL CANCER RESEARCH, 2022, 28 (20) : 4587 - 4587
  • [33] ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis
    Urso, Loredana
    Vernaci, Grazia
    Carlet, Jessica
    Lo Mele, Marcello
    Fassan, Matteo
    Zulato, Elisabetta
    Faggioni, Giovanni
    Menichetti, Alice
    Di Liso, Elisabetta
    Griguolo, Gaia
    Falci, Cristina
    Conte, Pierfranco
    Indraccolo, Stefano
    Guarneri, Valentina
    Dieci, Maria Vittoria
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] Elacestrant vs standard-of-care in ER+/HER2-advanced or metastatic breast cancer (mBC) with ESR1 mutation: key biomarkers and clinical subgroup analyses from the phase 3 EMERALD trial
    Bardia, Aditya
    O'Shaughnessy, Joyce
    Bidard, Francois-Clement
    Neven, Patrick
    Garcia-Saenz, Jose Angel
    Aftimos, Philippe
    Cortes, Javier
    Lu, Janice
    Tonini, Giulia
    Theall, Kathy Puvana
    Paoli, Alessandro
    Kaklamani, Virginia
    CANCER RESEARCH, 2024, 84 (09)
  • [35] Elacestrant vs Standard-of-Care in ER+/HER2- Advanced or Metastatic Breast Cancer (mBC) With ESR1 Mutation: Key Biomarkers and Clinical Subgroup Analyses From the Phase 3 EMERALD Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2024, 22 (01)
  • [36] Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2-metastatic breast cancer with an ESR1 mutation
    Goetz, Matthew
    Wander, Seth
    Bachelot, Thomas
    Batist, Gerald
    Cortes, Javier
    Cristofanilli, Massimo
    Curigliano, Giuseppe
    de Nonneville, Alexandre
    Yam, Einav Nili-Gal
    Jhaveri, Komal
    Ma, Cynthia
    Parsons, Heather
    Rugo, Hope
    Sammons, Sarah
    Stover, Daniel
    Twelves, Chris
    Bardia, Aditya
    Plourde, Paul V.
    Portman, David J.
    Damodaran, Senthil
    CANCER RESEARCH, 2024, 84 (09)
  • [37] Differential dynamics of fragmentomic and epigenetic circulating tumor DNA (ctDNA) features in first-line Palbociclib and Ribociclib treatment for Hormone Receptor (HR) positive, HER2 negative metastatic breast cancer (MBC)
    Noto, Claudia
    Cucciniello, Linda
    Molteni, Elisabetta
    Bolzonello, Silvia
    Franzoni, Alessandra
    Da Ros, Lucia
    Buriolla, Silvia
    Dri, Arianna
    Foffano, Lorenzo
    Spazzapan, Simon
    Russo, Stefania
    Pasto, Brenno
    Cudia, Giulia
    Targato, Giada
    Della Rossa, Serena
    Bonotto, Marta
    Minisini, Alessandro Marco
    Damante, Giuseppe
    Belletti, Barbara
    Gerratana, Lorenzo
    CANCER RESEARCH, 2024, 84 (09)
  • [38] Detecting actionable PIK3CA mutations through next-generation sequencing (NGS) in hormone receptor positive (HR+)/HER2-negative advanced/metastatic breast cancer (MBC): a real-life experience
    Caldart, A.
    Fiorio, E.
    Zanelli, S.
    Biondani, P.
    Parolin, V.
    Pellini, F.
    Montemezzi, S.
    Nottegar, A.
    Calio, A.
    Zampiva, I.
    Merler, S.
    Mongillo, M.
    Avesani, B.
    Borghesani, G.
    Giontella, E.
    Scarpa, A.
    Milella, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S38 - S39
  • [39] Genomic alterations detected by circulating tumor DNA and correlation with response to treatment with elacestrant, an oral selective estrogen receptor degrader, in phase 1 trials in postmenopausal women with ER+/HER2-advanced/metastatic breast cancer
    Bihani, Teeru
    Jung, JungAh
    Patel, Hitisha K.
    Bardia, Aditya
    Kabos, Peter
    Kaklamani, Virginia
    Jager, Agnes
    Aftimos, Philippe
    Wilks, Sharon
    de Vries, Elisabeth
    Harb, Wael
    Richards, Donald
    Weise, Amy
    Wesolowski, Robert
    van Oordt, Catharina C. W. Menke-van der Houven
    Conkling, Paul
    Neven, Patrick
    Conlan, Maureen G.
    CANCER RESEARCH, 2020, 80 (04)
  • [40] AKT1, ERBB2, ESR1, KRAS, PIK3CA and TP53 alteration detection by a new ctDNA assay in plasma of patients with hormone receptor positive (HR+)/HER2-advanced Breast Cancer treated with hormonal therapy and CDK4/6 inhibitors
    Virga, A.
    Gianni, C.
    Palleschi, M.
    Merloni, F.
    Maltoni, R.
    Ulivi, P.
    De Giorgi, U.
    Martinelli, G.
    Bravaccini, S.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 90 - 90
12345